2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
[PDF][PDF] 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
[HTML][HTML] Ferric carboxymaltose in heart failure with iron deficiency
Background Ferric carboxymaltose therapy reduces symptoms and improves quality of life in
patients who have heart failure with a reduced ejection fraction and iron deficiency …
patients who have heart failure with a reduced ejection fraction and iron deficiency …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
Background Previous studies have suggested that haemodynamic-guided management
using an implantable pulmonary artery pressure monitor reduces heart failure …
using an implantable pulmonary artery pressure monitor reduces heart failure …
Iron deficiency
Iron deficiency is one of the leading contributors to the global burden of disease, and
particularly affects children, premenopausal women, and people in low-income and middle …
particularly affects children, premenopausal women, and people in low-income and middle …
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …